ClinicalTrials.gg
CompletedNCT04683926Updated Apr 4, 2023Results posted

A Randomized Study Investigating Oral Desmetramadol Dose Proportionality and Food Effect In Normal Human Subjects

A Phase 1 interventional study of Desmetramadol in Pain, sponsored by Syntrix Biosystems, Inc.. Completed at 1 site in United States. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-04.

Sponsored by Syntrix Biosystems, Inc. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
19 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,886 studies in Pain with a site in United States — 315 open to participants now, 393 under way, 24 of them phase 3. Pain · United States.

Enrollment
1,987th of 2,564
24 · median 66
Started
2021
with 129 others
Phase 1
206 of 2,886
28 open now
Registered
2,199th of 2,886
by date

Among the 2,886 studies in Pain with a site in United States, this one is the 1,987th largest by enrollment of the 2,564 interventional ones that give a count, is one of 130 that started in 2021, is one of 206 in phase 1, and was the 2,199th registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

315 of the 2,886 studies in Pain with a site in United States are open now. Recruiting first, the newest first:

310 more — sign in →

All 315 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 19 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,886 studies in Pain with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to investigate in healthy human subjects how much desmetramadol (Omnitram) gets in the blood after different oral doses are taken with or without food.

Read the detailed description

An open-label, randomized, balanced, single-dose, four-treatment, four-period, four-sequence (using a Williams' square design) cross-over study with each dose separated by >3 days. There are 4 sequences (Sequence 1, Sequence 2, Sequence 3, and Sequence 4), and 4 Periods (Period I, Period II, Period III, and Period IV). Sequence 1 order is 30 mg dose with food (Period I); 30 mg dose fasted (Period II), 10 mg dose fasted (Period III), and 20 mg dose fasted (Period IV). Sequence 2 order is 10 mg dose fasted (Period I); 30 mg dose with food (Period II), 20 mg dose fasted (Period III), and 30 mg dose fasted (Period IV). Sequence 3 order is 20 mg dose fasted (Period I); 10 mg dose fasted (Period II), 30 mg dose fasted (Period III), and 30 mg dose with food (Period IV). Sequence 4 order is 30 mg dose fasted (Period I); 20 mg dose fasted (Period II), 30 mg dose with food (Period III), and 10 mg dose fasted (Period IV).

To account for potential dropouts, up to 32 eligible subjects will be randomized to obtain a target sample of 24 subjects with PK responses at each of the four treatment periods (based on our completed phase 1 study in 43 subjects, dropouts are unlikely (\~5%); see Section 1.2.2). Before each oral dose, subjects will be fasted overnight for at least 10 hours. Treatment sequences will include the following four unblinded single-dose oral treatments: 1) desmetramadol 1 x 10 mg tablet; 2) desmetramadol 2 x 10 mg tablets; 3) desmetramadol 3 x 10 mg tablets; and 4) desmetramadol 3 x 10 mg tablets following a high-fat, high-calorie breakfast served approximately 30 minutes before dosing and entirely consumed within 20 minutes. All subjects will fast for an additional four hours after desmetramadol administration. The fed treatment should be administered the desmetramadol dose approximately 30 minutes after the start of the meal. Desmetramadol will be administered with approximately 240 ml of water. No water is allowed one hour before and one hour after each desmetramadol administration.

This will be an inpatient study. Subjects will be admitted to the clinical pharmacology unit on Study Day -1, and administered a single oral dose treatment on Study Day 1, Study Day 4, Study Day 7 and Study Day 10. After completing study procedures on Day 11 the subject will be discharged from the facility.

Blood specimens for plasma preparation and PK analysis will be collected at the following times: pre-dose (0 h), and post-dose 0.5, 1.0, 1.5, 2.0, 2.5, 3, 3.5, 4, 6, 8, 12, 16, 24, and 32 h.

03

Conditions studied

  • Pain

Browse trials for

Keywords

  • Pharmacokinetics
  • Food effect
04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy males and females with vital signs as follows at screening: systolic blood pressure > 90 mm Hg and \< 140 mm Hg; diastolic blood pressure > 40 mm Hg and \< 90 mm Hg; pulse 40 to 99 beats per minute; respiratory rate 12 to 24 breathes per minute.
  2. Age 19 to 55 years.
  3. Able and willing to give
  4. Able to comply with all study procedures.
  5. If female, must not be of or must agree to use one or more of the following forms of from screening, throughout the study and for 30 days following study drug administration: hormonal (e.g., oral, transdermal, intravaginal, implant or injection for 3 months); double barrier (e.g., condom or diaphragm with spermicide); intrauterine device (IUD) or system (IUS) (for 3 months); vasectomized partner (6 months minimum); or abstinence.

    Screening laboratory results must be within normal range per clinical research unit: serum sodium, potassium, calcium, BUN, creatinine, , AST, total , alkaline phosphatase, glucose (random), albumin, total protein, WBC and differential, , and . In addition PT and must be \< 1.2 .

  6. (ECG) without abnormalities.

    Urinalysis demonstrating \< +1 glucose, and +1 protein.

  7. If female, must have a negative pregnancy test at screening
  8. Negative urine test for substances of abuse, including opiates, per clinical pharmacology unit standards at screening and clinic check-in.
  9. Negative serology tests for , surface antigen, and virus antibody.
  10. Weight > 50 Kg and a (BMI) of 18.0 to 32.0 kg/m (inclusive).
  11. Non-smoker of tobacco for a minimum of the past 3 months, and negative urine continine test.

Exclusion criteria

Exclusion Criteria:

  1. Oral temperature > 38°C or current illness.
  2. History of seizures, epilepsy, or recognized increase risk of seizure (e.g., head trauma, metabolic disorders, alcohol or drug withdrawal).
  3. History of cirrhosis or laboratory evidence of liver disease.
  4. Having undergone gall bladder removal.
  5. Use of alcohol within 24 hours of day -1 until the end of the study; and grapefruit, grapefruit-related citrus fruits (e.g., Seville oranges, pomelos), or grapefruit juice or grapefruit-related juices within 7 days of study drug administration and until the end of the study.
  6. History of previous anaphylaxis, severe allergic reaction to tramadol, codeine, or other opioid drugs.
  7. Any other unstable acute or chronic disease that could interfere with the evaluation of the safety of the study drug as determined by the principal Investigator in dialogue with the Sponsor Medical Monitor.
  8. Females must not be currently pregnant or breast feeding.
  9. Unlikely to comply with the study protocol.
  10. Known or suspected alcohol or drug abuse within the past 6 months.
  11. Received another agent within 4 weeks of Day -1, or within five half-lives of Day -1, whichever is longer; or receiving any other investigational agent during this study.
  12. Any concurrent disease or condition that in the opinion of the investigator impairs the subject's ability to complete the trial. Psychological, familial, sociological, geographical or medical conditions which, in the Investigator's opinion, could compromise compliance with the objectives and procedures of this protocol, or obscure interpretation of the trial data.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Desmetramadol 10 mg, fasted

    While fasting a single oral dose of 10 mg desmetramadol under.

    Drug: Desmetramadol

  • Experimental
    Desmetramadol 20 mg, fasted

    While fasting a single oral dose of 20 mg desmetramadol.

    Drug: Desmetramadol

  • Experimental
    Desmetramadol 30 mg , fasted

    While fasting a single oral dose of 30 mg desmetramadol.

    Drug: Desmetramadol

  • Experimental
    Desmetramadol 30 mg , fed

    After feeding a single oral dose of 30 mg desmetramadol.

    Drug: Desmetramadol

Interventions

  • DrugDesmetramadol

    Analgesic

    Also known as: Omnitram

06

What researchers measure

Primary outcomes

  1. (-/+)-M1, AUC(0-32) and AUC(Inf)

    The AUC(0-32) and AUC(inf) of (-/+)-M1 after each treatment (i.e., 10, 20 and 30 mg desmetramadol fasted, and 30 mg desmetramadol fed)

    Time frame: Pre-dose (0 h), and post-dose 0.5, 1.0, 1.5, 2.0, 2.5, 3.0 ,3.5, 4, 6, 8, 12, 16, 24, and 32 h.

  2. (-/+)-M1, Cmax

    The Cmax of (-/+)-M1 after each treatment (i.e., 10, 20 and 30 mg desmetramadol fasted, and 30 mg desmetramadol fed)

    Time frame: Pre-dose (0 h), and post-dose 0.5, 1.0, 1.5, 2.0, 2.5, 3.0 ,3.5, 4, 6, 8, 12, 16, 24, and 32 h.

Secondary outcomes

  1. Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment.

    Adverse events will include: 1) reports by participants; 2) observations by investigators; and 3) abnormal laboratory safety test results.

    Time frame: Participant report adverse events throughout study enrolment; investigators observe adverse events during all 11 days of inpatient treatment; laboratory safety labs are obtained on Day 11 (the final study day).

07

Results

Posted Apr 4, 2023

Participant flow

Intervention 1 (1 Day)
Participant flow — Intervention 1 (1 Day)
MilestoneA-B-D-CB-C-A-DC-D-B-AD-A-C-B
Started6666
Completed6666
Not completed0000
Washout 1 (3 Days)
Participant flow — Washout 1 (3 Days)
MilestoneA-B-D-CB-C-A-DC-D-B-AD-A-C-B
Started6666
Completed6666
Not completed0000
Intervention 2 (1 Day)
Participant flow — Intervention 2 (1 Day)
MilestoneA-B-D-CB-C-A-DC-D-B-AD-A-C-B
Started6666
Completed6665
Not completed0001
Withdrew: Adverse event0001
Washout 2 (3 Days)
Participant flow — Washout 2 (3 Days)
MilestoneA-B-D-CB-C-A-DC-D-B-AD-A-C-B
Started6665
Completed6665
Not completed0000
Intervention 3 (1 Day)
Participant flow — Intervention 3 (1 Day)
MilestoneA-B-D-CB-C-A-DC-D-B-AD-A-C-B
Started6665
Completed6665
Not completed0000
Washout 3 (3 Days)
Participant flow — Washout 3 (3 Days)
MilestoneA-B-D-CB-C-A-DC-D-B-AD-A-C-B
Started6665
Completed6665
Not completed0000
Intervention 4 (1 Day)
Participant flow — Intervention 4 (1 Day)
MilestoneA-B-D-CB-C-A-DC-D-B-AD-A-C-B
Started6665
Completed6665
Not completed0000

Outcome measures

Primary(-/+)-M1, AUC(0-32) and AUC(Inf)

The AUC(0-32) and AUC(inf) of (-/+)-M1 after each treatment (i.e., 10, 20 and 30 mg desmetramadol fasted, and 30 mg desmetramadol fed)

Time frame:
Pre-dose (0 h), and post-dose 0.5, 1.0, 1.5, 2.0, 2.5, 3.0 ,3.5, 4, 6, 8, 12, 16, 24, and 32 h.
Reported as:
Mean · ng*hr/mL
(-/+)-M1, AUC(0-32) and AUC(Inf)
ng*hr/mLDesmetramadol 10 mg, FastedDesmetramadol 20 mg, FastedDesmetramadol 30 mg, FastedDesmetramadol 30 mg, Fed
AUC(0-32), (-/+)-M1136.0 ± 30.5274.9 ± 61.3408.8 ± 86.0450.7 ± 103.6
AUC(inf), (-/+)-M1138.0 ± 31.1279.0 ± 62.1414.6 ± 87.8454.4 ± 105.4
Statistical analysis
  • Desmetramadol 10 mg, Fasted vs Desmetramadol 20 mg, Fasted vs Desmetramadol 30 mg, Fasted · Auc(0-36) estimate (β1): 1.0227
  • Desmetramadol 10 mg, Fasted vs Desmetramadol 20 mg, Fasted vs Desmetramadol 30 mg, Fasted · Auc(inf) estimate (β1): 1.0223
  • Desmetramadol 30 mg, Fasted vs Desmetramadol 30 mg, Fed · Auc(0-inf) fed/fasted ratio: 1.09 · 90% CI 1.05 to 1.12
Primary(-/+)-M1, Cmax

The Cmax of (-/+)-M1 after each treatment (i.e., 10, 20 and 30 mg desmetramadol fasted, and 30 mg desmetramadol fed)

Time frame:
Pre-dose (0 h), and post-dose 0.5, 1.0, 1.5, 2.0, 2.5, 3.0 ,3.5, 4, 6, 8, 12, 16, 24, and 32 h.
Reported as:
Mean · ng/mL
(-/+)-M1, Cmax
ng/mLDesmetramadol 10 mg, FastedDesmetramadol 20 mg, FastedDesmetramadol 30 mg, FastedDesmetramadol 30 mg, Fed
(-/+)-M1, Cmax12.41 ± 2.5924.22 ± 5.0836.27 ± 7.4743.42 ± 10.73
Statistical analysis
  • Desmetramadol 10 mg, Fasted vs Desmetramadol 20 mg, Fasted · Cmax estimate (β1): 0.9899
  • Desmetramadol 30 mg, Fasted vs Desmetramadol 30 mg, Fed · Cmax 90% fed/fasted ratio: 1.18 · 90% CI 1.08 to 1.28
SecondaryNumber of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment.

Adverse events will include: 1) reports by participants; 2) observations by investigators; and 3) abnormal laboratory safety test results.

Time frame:
Participant report adverse events throughout study enrolment; investigators observe adverse events during all 11 days of inpatient treatment; laboratory safety labs are obtained on Day 11 (the final study day).
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment.
ParticipantsDesmetramadol 10 mg, FastedDesmetramadol 20 mg, FastedDesmetramadol 30 mg , FastedDesmetramadol 30 mg , Fed
Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment.3456

Adverse events

Collected over 11 days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Desmetramadol 10 mg, Fasted0/24 (0%)0/24 (0%)3/24 (12.5%)
Desmetramadol 20 mg, Fasted0/23 (0%)0/23 (0%)4/23 (17.4%)
Desmetramadol 30 mg , Fasted0/23 (0%)0/23 (0%)5/23 (21.7%)
Desmetramadol 30 mg , Fed0/23 (0%)0/23 (0%)6/23 (26.1%)
Most frequent other events
Showing 10 of 23
Most frequent other events
EventDesmetramadol 10 mg, FastedDesmetramadol 20 mg, FastedDesmetramadol 30 mg , FastedDesmetramadol 30 mg , Fed
DizzinessNervous system disorders0/240/233/232/23
NauseaGastrointestinal disorders0/240/232/231/23
FatigueGeneral disorders0/240/231/232/23
PalpitationsCardiac disorders0/240/231/230/23
Erythema of eyelidEye disorders0/240/230/231/23
Periorbital swellingEye disorders0/240/230/231/23
ConstipationGastrointestinal disorders1/240/230/231/23
VomitingGastrointestinal disorders0/240/231/230/23
Feeling abnormalGeneral disorders0/240/230/231/23
Localised oedemaGeneral disorders0/240/230/231/23

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)A-B-D-CB-C-A-DC-D-B-AD-A-C-BTotal
<=18 years00000
Between 18 and 65 years666624
>=65 years00000
Sex: Female, Male
Sex: Female, Male(Participants)A-B-D-CB-C-A-DC-D-B-AD-A-C-BTotal
Female243312
Male423312
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)A-B-D-CB-C-A-DC-D-B-AD-A-C-BTotal
Hispanic or Latino11125
Not Hispanic or Latino555419
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)A-B-D-CB-C-A-DC-D-B-AD-A-C-BTotal
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American20215
White464519
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(participants)A-B-D-CB-C-A-DC-D-B-AD-A-C-BTotal
United States666624
08

Study locations

1 site
  • Celerion
    Lincoln, Nebraska 68502, United States
09

References and documents

Publications

  • Zebala JA, Searle SL, Webster LR, Johnson MS, Schuler AD, Maeda DY, Kahn SJ. Desmetramadol Has the Safety and Analgesic Profile of Tramadol Without Its Metabolic Liabilities: Consecutive Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Trials. J Pain. 2019 Oct;20(10):1218-1235. doi: 10.1016/j.jpain.2019.04.005. Epub 2019 Apr 18. PubMed 31005596 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Jan 2021, 0 months.

Results were first posted in Apr 2023, 2 years 2 months after primary completion.

Of 104 industry-sponsored phase 1 interventional studies under Pain, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 9. This study's 0 months is below that.

Counting every sponsor, half of 222 studies reached it within 9 months; a quarter within 3 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2020
First posted
Dec 24, 2020
StartActual
Jan 8, 2021
Primary completionActual
Jan 18, 2021
CompletionActual
Jan 18, 2021
Results first posted
Apr 4, 2023
Last update
Apr 4, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04683926
Lead sponsor
Syntrix Biosystems, Inc.
Responsible party
Sponsor
First posted
Dec 24, 2020
Start date
Jan 8, 2021
Primary completion
Jan 18, 2021
Completion
Jan 18, 2021
Results posted
Apr 4, 2023
Last update
Apr 4, 2023

Study contacts

Robert Schwab, MD
principal investigator · Celerion
Stuart Kahn, MD
study director · Syntrix Biosystems

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion